Lacutamab Biosimilar - Research Grade

Human

KIR3DL2

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P43630

3812

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-KIR3DL2 antibody lacutamab, supplied for research use only (RUO). It is a fully recombinant human IgG1/kappa protein built around the KIR3DL2 (CD158k) target and is not the clinical drug; it is not intended for human or veterinary use. Because lacutamab acts largely through Fc-mediated effector recruitment, an intact human IgG1 backbone makes this analog useful for interrogating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against KIR3DL2-expressing cells. Typical research applications include target-binding and specificity assays, use as an isotype-matched positive control, effector-function and Fc-engineering benchmarking, flow-cytometry detection of KIR3DL2+ populations, and biosimilar/comparability characterization in in-vitro and preclinical settings. It is manufactured to research-grade specifications with low endotoxin (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support screening, assay development, and reproducible batch work. Ichorbio should confirm format, buffer, and endotoxin grade against the intended assay. KIR3DL2 (CD158k; UniProt P43630) is a member of the killer-cell immunoglobulin-like receptor (KIR) family, characterized by three extracellular Ig-like domains and a long cytoplasmic tail bearing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). On normal immune cells it functions as an inhibitory receptor, expressed on subsets of NK cells and on some CD8+ and gamma-delta T cells, where engagement dampens cytotoxic responses; reported ligands include HLA-A3/A11 and CpG oligodeoxynucleotides. Its principal research and clinical interest stems from restricted, high-frequency surface expression on malignant T cells in cutaneous T-cell lymphomas, notably Sezary syndrome and transformed mycosis fungoides, where it marks the neoplastic clone. This tumor-associated expression pattern makes KIR3DL2 both a diagnostic/flow-cytometric marker and an antibody-targetable surface antigen for effector-mediated depletion of the malignant population.

CD158 antigen-like family member K, Natural killer-associated transcript 4, NKAT-4, p70 natural killer cell receptor clone CL-5, p70 NK receptor CL-5, Killer cell immunoglobulin-like receptor 3DL2, CD158K

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Lacutamab (anti-KIR3DL2) Biosimilar

Q: Is the Lacutamab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lacutamab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lacutamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lacutamab that binds KIR3DL2; for research use only.